18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 2070-

  Fassan, Matteo ^a   Pizzi, Sara ^a   Sperti, Cosimo ^a   Pasquali, Claudio ^a   Pedrazzoli, Sergio ^a   Chierichetti, Franca ^a   Parenti, Anna Rosita ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER DIAGNOSIS; CANCER STAGING; DRUG UPTAKE; DYSPLASIA; HUMAN; IMMUNOREACTIVITY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; LETTER; POSITRON EMISSION TOMOGRAPHY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; AGED; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; SCINTISCANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 57149106318     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054924     Document Type: Letter

References (10)

1. Ban S, Naitoh Y, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol. 2006;30:1561-1569.
2. Furukawa T, Kloeppel G, Adsay NV, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447:794-799.
3. Sperti C, Bissoli S, Pasquali C, et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2007;246:932-939.
4. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
5. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
6. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727-1735.
7. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
8. Parenti A, Sperti C, Porzionato A, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2008; in press.
9. Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136:548-556.
10. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005;46:675-682.